Conflict of interest DK has received research support from Sanofi, Tanabe Pharma, Terumo, Behringer Ingelheim, Kyowa Kirin, Sumitomo Dainippon Pharma, Ono Pharmaceutical and Takeda Pharmaceutical as well as speaker honoraria from Novo Nordisk Pharma, Sanofi, and Takeda Pharmaceutical
Lancet 2005;366:1279-1289
Faster return to running through effective treatment carries significant practical value for serious runners
Are GLP-1 medications like Ozempic or Wegovy FDA-approved for addiction treatment
As a general rule, people in their 18-65 are the most common candidates
How are Tirzepatide injections administered